SELLAS (SLS) Stock: Why It Fell 13% With No New Trial News

Quick answer

SELLAS Life Sciences stock fell 13.5% to $9.81 at 12:53pm ET on Oct 16, 2026, down from an $11.34 close, after dropping as low as $9.75 in the first half hour of trading. We found no company news behind it: SELLAS issued no press release, its last SEC filing was the Aug 11 quarterly report, and nothing new came out about its Phase 3 REGAL trial. Biotech sold off as a group, with the SPDR S&P Biotech ETF (XBI) down 3.3% and the Nasdaq 100 fund down 1.8%, and SELLAS fell about four times as hard as the sector fund. That fits a stock whose value rests almost entirely on one trial readout, with a beta near 2.7 and short interest of 27.6% of its float. The shares are now 21% below their $12.41 close on Oct 13 and about 38% below the $15.88 high of June 30.

Our view: Bearish through November 12, 2026, around when SELLAS is expected to report third-quarter results (it filed last year's third-quarter 10-Q on Nov 12, 2025). Three facts point down. The REGAL trial has sat at 78 of the 80 deaths it needs since May 11, and SELLAS has said it will announce the 80th event when it occurs, so each week without an announcement pushes the readout later. About 93% of the roughly $1.98 billion market value rests on the pipeline, mostly that one readout. And the third-quarter 10-Q will show whether SELLAS sold stock under its $150 million at-the-market program after June 30. On the other side, the drop added no facts about the trial, cash was $138.3 million at June 30 with no at-the-market sales, and 27.6% of the float is sold short, which can force sharp rallies. Those support the balance sheet but do not bring the readout closer. We would move to Bullish if SELLAS announces the 80th event with a timeline for topline data, or if first-line SLS009 data due in the fourth quarter are clearly positive. This is a view on direction over that window, not a recommendation to trade the stock.

SELLAS daily closing price from Aug 24 to Oct 16, 2026, with the Aug 28 drop, the Oct 13 close and the Oct 16 slide marked

Key takeaways

SELLAS fell 13.5% to $9.81 at 12:53pm ET on Oct 16, from an $11.34 close, after touching $9.75 in the first half hour. The company issued no release and filed nothing with the SEC.
Biotech fell as a group: the SPDR S&P Biotech ETF (XBI) was down 3.3% and AML peers Kura Oncology and Syndax were down 3.6% and 4.0%. SELLAS fell about four times as much as the sector fund.
The Phase 3 REGAL trial of galinpepimut-S needs 80 deaths to trigger its final analysis. The last count the company disclosed was 78, as of May 11, 2026, five months ago.
Cash was $138.3 million at June 30 against $16.4 million of operating cash burn in the first half, with no shares sold under a $150 million at-the-market program, per the 10-Q.
Our view is Bearish through November 12, 2026: the trial has sat two deaths from its trigger since May, and most of the market value rests on a readout that keeps moving later.

Table of contents

Oct 16, 2026: a fast drop at the open, then no bounce
The REGAL trial: two deaths from the trigger, five months on
The numbers
The bull case
The risks
What comes next

Oct 16, 2026: a fast drop at the open, then no bounce

SELLAS traded between $11.28 and $11.38 in thin premarket trading, close to the prior close. It opened at $11.17, touched $11.24, and fell quickly: from $10.79 at 9:40am it dropped to $9.75 just before 9:55am, with about 1.6 million shares changing hands in those ten minutes. It bounced to $10.35 by 10:15am, then drifted lower for the rest of the morning and was at $9.81 at 12:53pm. Volume had reached 10.5 million shares, about twice the 20-day average.

What pushed it down:

A broad biotech selloff. At 12:56pm:

Stock or fund	Change
SELLAS (SLS)	-13.4%
Syndax Pharmaceuticals (SNDX)	-4.0%
Kura Oncology (KURA)	-3.6%
SPDR S&P Biotech ETF (XBI)	-3.3%
Geron (GERN)	-2.9%
iShares Biotechnology ETF (IBB)	-2.3%
Invesco QQQ (QQQ)	-1.8%
SPDR S&P 500 ETF (SPY)	-0.8%

Syndax and Kura also sell or develop leukemia drugs, and Geron sells a blood cancer drug, so they are the closest listed comparisons. All fell less than 5%.

No company news. SEC EDGAR shows no 8-K since Aug 11, and the most recent company release was preclinical pancreatic cancer data on Sep 25. Same-day reports from MarketBeat and Tickeron gave no specific cause either. Tickeron pointed to the sector selloff and to holders unwilling to carry the stock into a binary trial result.
An old overhang resurfacing. StocksToTrade and other sites ran items on Oct 16 about the Pomerantz LLP investigation. The firm's notices date from Oct 1 to Oct 7, so nothing in them was new today.
A crowded, volatile stock. Short sellers held 55.1 million shares, 27.6% of the float, and the shares had run up from $11.26 on Oct 8 to $12.41 on Oct 13 as retail traders talked up a possible buyout, a theory Stocktwits reported but no company or buyer has supported. A stock with that setup tends to fall harder than its sector on a down day.

After the drop, RSI(14) stood at 35, the shares sat 21% below their 50-day average and 20% above their 200-day average, volume ran 2.0 times its 20-day average, and the stock was 38% below its 52-week high of $15.88.

The gap between SELLAS and its peers is real, but we could not tie it to any new fact. The most likely reading is that a high-beta stock with a large short position fell hardest on a weak day for biotech.

The REGAL trial: two deaths from the trigger, five months on

REGAL is a randomized, open-label Phase 3 trial of galinpepimut-S, a peptide vaccine aimed at the WT1 protein, against the best available treatment as maintenance therapy for acute myeloid leukemia patients in second complete remission. The primary endpoint is overall survival, and the final analysis is triggered when the trial records its 80th death across both arms.

Bar chart of REGAL trial event counts: 72 at Dec 26, 2025, 78 at May 11, 2026, against the trigger of 80

The count has moved slowly. SELLAS reported 72 events as of Dec 26, 2025, and said then that it had expected the 80th before year-end. The contract research organization reported 78 as of May 11, 2026, per the 10-Q. On Aug 11, CEO Angelos Stergiou said the company was "approaching the pre-specified 80th event" and that a successful result could lead to "a potential BLA submission to the FDA." The company says it remains blinded to outcomes and will announce the 80th event when it occurs. The independent data monitoring committee recommended the trial continue without changes after its pre-specified interim analysis.

Slow event accrual in a survival trial can mean patients in one or both arms are living longer than planned, but the company cannot see which arm, and neither can investors. That is why the readout is binary. Our explainer on probability-weighted valuation for binary events shows how to think about a stock priced on one outcome.

Two outside claims muddied the timeline. On Aug 21 the stock rose about 15% after a German financial site reported the trial had reached 80 events, per Stocktwits, and on Aug 28 it fell 13.15% to $13.21 after another news report said the same, per Pomerantz. SELLAS confirmed neither. Pomerantz's Oct 1 notice says it is investigating whether the company and some officers or directors engaged in securities fraud; it is an investigation, not a filed lawsuit.

The numbers

Item	Figure	Source
Cash and equivalents, June 30, 2026	$138.3 million	10-Q
Cash, Dec 31, 2025	$71.8 million	10-Q
Operating cash used, first half 2026	$16.4 million	10-Q
Q2 net loss	$9.6 million	10-Q
Q2 R&D / G&A expense	$6.3 million / $4.4 million	Q2 release
Warrant exercise proceeds, first half 2026	$82.9 million	10-Q
Shares outstanding, Aug 10, 2026	201.9 million	10-Q
Market value at $9.81	about $1.98 billion	Market data

The company says its cash will fund planned operations "for at least the next twelve months." At the first-half burn rate, $138.3 million would last more than four years by our arithmetic, though costs will rise if REGAL succeeds and a license application follows. Cash comes to about $0.69 a share, so roughly 93% of the market value rests on the pipeline, mostly REGAL.

The dilution risk sits in one program. SELLAS has a $150 million at-the-market facility with TD Cowen, set up in March 2026, and had sold nothing under it as of the 10-Q. Our guide to dilution and share count changes covers why an unused program still weighs on a stock.

The bull case

The readout is close. Two more deaths trigger the final analysis, and the company has said it is preparing for a possible license application.
The balance sheet is clean. Debt is near zero, cash nearly doubled this year without any at-the-market sales, and the company does not need to raise money before the readout.
A second shot. A randomized 80-patient Phase 2 trial of SLS009 (tambiciclib) in newly diagnosed AML had enrolled 28 patients by Aug 10, and SELLAS expects topline data in the fourth quarter of 2026.
Analyst targets sit well above the price. The consensus target of $35, though it rests on a single estimate.

The risks

One binary outcome. If REGAL fails on overall survival, most of the market value goes with it.
Timing keeps slipping. The company expected the 80th event in 2025. It has not arrived ten months later.
Legal overhang. The Pomerantz investigation could turn into a class action, which would add cost and distraction.
Dilution. The $150 million at-the-market program gives the company room to sell stock, especially if a positive result raises the price.
Crowded trading. With 27.6% of the float sold short and a beta near 2.7, the stock can move far more than its news on any given day. The short interest and squeeze risk explainer covers how that cuts both ways.

What comes next

The 80th event announcement. It has no date. It starts database lock and unblinding; topline results would follow later. See our guide to regulatory approvals as catalysts for how the steps after a readout usually run.
Third-quarter results, expected around Nov 12. Watch the event count, cash, any at-the-market sales and the share count.
SLS009 topline data, guided for the fourth quarter.
The ASH annual meeting, Dec 12 to Dec 15 in New Orleans, where SELLAS has a booth, per Stocktwits.

Frequently asked questions

Why did SELLAS stock drop today?

We found no company-specific cause. SELLAS issued no press release and filed nothing with the SEC on Oct 16. Biotech stocks fell broadly, with XBI down 3.3%, and SELLAS, a stock with a beta near 2.7 and short interest of 27.6% of its float, fell about four times as much. The wait for the REGAL trial's 80th event and a law firm investigation opened in October add to the pressure on sentiment, but neither produced news today.

Has the REGAL trial reached its 80th event?

SELLAS has not said so. Its last disclosed count was 78 pooled events as of May 11, 2026, and in its Aug 11 results it said it was approaching the 80th event and will announce it when it occurs. Outside reports in August claimed the 80th event had been reached, but the company has not confirmed them.

What happens after the 80th event?

The 80th death triggers the final overall survival analysis. Results still need database lock, statistical analysis and unblinding before topline data can be released, so the readout comes some time after the trigger, not on the day.

How much cash does SELLAS have?

Cash and cash equivalents were $138.3 million at June 30, 2026, up from $71.8 million at the end of 2025, mostly from $82.9 million of warrant exercises in the first half. The company says that is enough to fund planned operations for at least twelve months from the filing date.

Is SELLAS selling stock?

Not as of its last filing. It has a $150 million at-the-market program with TD Cowen, set up in March 2026, and the 10-Q says no shares had been sold under it. Any sales would show up in the third-quarter 10-Q.

What is the Pomerantz investigation about?

Pomerantz LLP said on Oct 1 that it is investigating whether SELLAS and some officers or directors engaged in securities fraud, citing an Aug 28 news report that the REGAL trial had reached its 80th death and the 13.15% drop that day. It is an investigation notice, not a lawsuit, and no wrongdoing has been established.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published October 16, 2026 · 7 min read · Options and Catalysts